Bristol Myers Squibb (BMY) to Release Earnings on Thursday

Bristol Myers Squibb (NYSE:BMY) is expected to be posting its Q4 2025 results before the market opens on Thursday, February 5th. Analysts expect Bristol Myers Squibb to post earnings of $1.65 per share and revenue of $12.2373 billion for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 5, 2026 at 8:00 AM ET.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, topping analysts’ consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The business had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. During the same period in the prior year, the company earned $1.80 EPS. Bristol Myers Squibb’s revenue for the quarter was up 2.8% on a year-over-year basis. On average, analysts expect Bristol Myers Squibb to post $7 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Bristol Myers Squibb Trading Down 1.6%

BMY stock opened at $54.66 on Thursday. The business has a fifty day moving average price of $53.07 and a 200 day moving average price of $48.55. The company has a debt-to-equity ratio of 2.39, a current ratio of 1.27 and a quick ratio of 1.17. Bristol Myers Squibb has a fifty-two week low of $42.52 and a fifty-two week high of $63.33. The stock has a market capitalization of $111.26 billion, a price-to-earnings ratio of 18.46, a P/E/G ratio of 0.17 and a beta of 0.29.

Bristol Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.6%. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date is Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio is 85.14%.

Analysts Set New Price Targets

BMY has been the topic of several research reports. HSBC reiterated a “hold” rating and set a $53.00 price target on shares of Bristol Myers Squibb in a research report on Wednesday, December 10th. Piper Sandler reiterated an “overweight” rating and set a $66.00 target price (up from $62.00) on shares of Bristol Myers Squibb in a research report on Wednesday. Bank of America raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and increased their price target for the company from $52.00 to $61.00 in a research note on Monday, December 15th. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. Seven analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $57.43.

Institutional Trading of Bristol Myers Squibb

A number of institutional investors have recently bought and sold shares of the business. Man Group plc increased its position in shares of Bristol Myers Squibb by 280.4% in the 2nd quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock valued at $345,594,000 after buying an additional 5,503,391 shares in the last quarter. Two Sigma Investments LP increased its holdings in shares of Bristol Myers Squibb by 530.6% in the third quarter. Two Sigma Investments LP now owns 5,453,357 shares of the biopharmaceutical company’s stock worth $245,946,000 after acquiring an additional 4,588,601 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Bristol Myers Squibb by 56.0% during the third quarter. AQR Capital Management LLC now owns 9,463,981 shares of the biopharmaceutical company’s stock worth $426,352,000 after purchasing an additional 3,396,041 shares during the period. Deerfield Management Company L.P. bought a new position in shares of Bristol Myers Squibb during the 3rd quarter valued at about $105,433,000. Finally, State Street Corp grew its position in shares of Bristol Myers Squibb by 2.0% in the 3rd quarter. State Street Corp now owns 96,595,232 shares of the biopharmaceutical company’s stock valued at $4,356,445,000 after purchasing an additional 1,855,238 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.